Just a few weeks after drug manufacturer Novartis was ordered to forfeit the rights to four topical skincare medications as part of a deal to acquire Fougera Pharmaceuticals (https://www.ftc.gov/opa/2012/07/novartis.shtm), Sandoz, a division of Novartis, has completed the acquisition of Fougera on a cash and debt-free basis.
Fougera’s dermatology development and portfolio of products is strong and includes semi-solid forms like creams and ointments as well as a well known branded business, PharmaDerm. The acquisition also allows Sandoz to leverage both its leading position in the US generics sector and its presence in more than 140 countries to expand Fougera’s broad dermatology portfolio to new markets around the world.
"We are pleased to combine Fougera's strong portfolio and pipeline of dermatology medicines with Sandoz's existing global leadership positions in biosimilars and generic injectables, ophthalmics and antibiotics," explains Jeff George, Sandoz's global head. "This will significantly enhance the range of affordable, high-quality medicines that Sandoz can offer to patients and payors in the US and around the world."
Fougera Pharmaceuticals was found in 1849 and is based in Melville, NY. With the acquisition, Fourgera will now be integrated into Sandoz’s US business, which is based in Princeton, NJ, but will continue to exist as a separate legal entity, according to news reports on the acquisition.
For more information, please visit https://on.mktw.net/NLN8s0.
Just a few weeks after drug manufacturer Novartis was ordered to forfeit the rights to four topical skincare medications as part of a deal to acquire Fougera Pharmaceuticals (https://www.ftc.gov/opa/2012/07/novartis.shtm), Sandoz, a division of Novartis, has completed the acquisition of Fougera on a cash and debt-free basis.
Fougera’s dermatology development and portfolio of products is strong and includes semi-solid forms like creams and ointments as well as a well known branded business, PharmaDerm. The acquisition also allows Sandoz to leverage both its leading position in the US generics sector and its presence in more than 140 countries to expand Fougera’s broad dermatology portfolio to new markets around the world.
"We are pleased to combine Fougera's strong portfolio and pipeline of dermatology medicines with Sandoz's existing global leadership positions in biosimilars and generic injectables, ophthalmics and antibiotics," explains Jeff George, Sandoz's global head. "This will significantly enhance the range of affordable, high-quality medicines that Sandoz can offer to patients and payors in the US and around the world."
Fougera Pharmaceuticals was found in 1849 and is based in Melville, NY. With the acquisition, Fourgera will now be integrated into Sandoz’s US business, which is based in Princeton, NJ, but will continue to exist as a separate legal entity, according to news reports on the acquisition.
For more information, please visit https://on.mktw.net/NLN8s0.
